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Abstract: Obesity is recognised as a condition of low-grade chronic inflammation resulting from macrophage infiltration 
of adipose tissue and activation of inflammatory pathways by oxidative stress mechanisms that lead to the development of 
insulin resistance. Various natural bioactive compounds (NBCs) with anti-inflammatory and anti-oxidant effects may im-
prove adipocyte dysfunction associated with metabolic syndrome. The present review focuses on the effects of phenolic 
compounds, n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and lipoic acid (LA) on the pathophysiological 
mechanisms of obesity. In this review, a total of 120 studies were included, and data thus obtained reflect beneficial 
physiological effects of n-3 LC-PUFA, LA and different phenolic compounds, including kaempferol, luteolin, apigenin, 
quercetin, resveratrol, curcumin, catechins, phenolic acids, in the prevention and/or attenuation of metabolic disturbances 
associated with obesity. Additionally, information from clinical studies provides new insights for defining the dose-
response relationship of dietary compounds, necessary time of exposure and potential side effects of these NBCs in the 
treatment of obesity and indicates further study is needed to verify these relationships. 
Keywords: Insulin resistance, Lipoic acid, Metabolic disturbances, n-3 Long-chain polyunsaturated fatty acids, Obesity treat-
ment, Phenolic compounds. 
INTRODUCTION 
 Obesity is considered a major public health problem 
worldwide and its prevalence continues to rise uncontrolla-
bly [1]. In clinical practice, it is quite obvious that metabolic 
alterations in obese individuals limit the likelihood of posi-
tive response to treatment while favouring the evolution of 
the metabolic syndrome as well as the development of co-
morbidities such as diabetes and vascular complications [2]. 
Primary strategies for the treatment of obesity are reduction 
of dietary energy intake and increase of physical energy ex-
penditure, and lifestyle changes are important for long-term 
success. However, a large percentage of patients to whom 
such treatment is recommended regain most of the weight 
lost during the treatment in subsequent months or years, and 
it is common for them to resort to expensive surgery, an in-
vasive procedure, in an effort to achieve long-term weight 
loss. Thus, healthcare practitioners and the general public 
continue to seek more effective strategies for obesity preven-
tion and management [3]. 
 There is a great interest in finding adjuvant therapy for 
the treatment of obesity to correct or mitigate metabolic  
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changes that increase inflammation, oxidative stress and the 
occurrence of comorbidities, particularly insulin resistance. 
Attenuation of inflammation and oxidative stress, and in-
creased fatty acids oxidation in the adipose tissue are impor-
tant points to improve the metabolism, reducing the risk of 
comorbidities [4-9]. Fig. (1), shows a representative scheme 
of the mechanisms related to oxidative stress and inflamma-
tion in obesity. 
 Natural bioactive compounds (NBCs) are substances 
contained in foods that provide a verifiable benefit to human 
health. Evidence has been shown that different NBCs modu-
late inflammatory genes by acting through various signalling 
pathways [10]. Moreover, some NBCs have the potential to 
improve adipocyte dysfunction associated with metabolic 
syndrome [11] as well as favour fatty acid oxidation and 
reduce lipogenesis [12]. The modulation of signalling path-
ways by anti-oxidant NBCs results in increased defence of 
several tissues against electrophilic stressors and oxidative 
insults; intervention in these pathways is therefore a strategy 
for the prevention and treatment of metabolic diseases asso-
ciated with oxidative stress [13].  
 The aim of the present study is to review recent findings 
concerning the effects of three types of NBCs (phenolic 
compounds, n-3 LC-PUFA and lipoic acid) on obesity, in-
cluding their mechanisms of action on adipocytes and on 
systemic levels. 
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Fig. (1). Mechanisms related to oxidative stress and inflammation in obesity. 
↑, increase; ↓, reduction; ∆, activation; TEE, total energy expenditure; ROS, reactive oxygen species; NADPH-oxidase, nicotinamide adenine 
dinucleotide phosphate-oxidase. 
PHENOLIC COMPOUNDS  
 Polyphenols (including flavonoids and resveratrol) and 
phenolic acids have demonstrated anti-inflammatory and 
anti-adipogenic activities in several types of animal and hu-
man cells, both in in vitro (Table 1) and in vivo models (Ta-
ble 2). 
Kaempferol, Luteolin and Apigenin 
 Kaempferol, luteolin and apigenin (Fig. 2 a, b, c) are 
flavonoids that have attracted great attention due to their 
ability to reduce the risks of chronic diseases through anti-
inflammatory activity [14] and to alter the immune function 
by inhibiting enzymes that are activated in inflammatory 
conditions. Inactivated enzymes include the family of mito-
gen-activated protein kinases (MAPK - ERK, JNK and P38) 
that belong to the TNF-α signalling pathway, which activates 
nuclear factor kappa B (NF-κB) [15]. 
 In vitro studies, described in Table 1, have demonstrated 
the anti-inflammatory effects of kaempferol, luteolin and 
apigenin in different cell types. Macrophages, endothelial 
cells and 3T3-L1 adipocytes treated with kaempferol, luteo-
lin and apigenin have shown reduced inflammatory re-
sponses. Moreover, kaempferol and luteolin induce the  
 
activation of PPAR-γ and its target genes (such as leptin, 
GLUT4 and adiponectin) as well as enhance insulin sensitiv-
ity in adipocytes [16-21]. Apigenin-induced activation of 
AMP-activated protein kinase (AMPK) that reduced the ex-
pression of adipogenic genes, thus suppressing adipogenesis 
in 3T3-L1 cells [22]. 
 Kaempferol, apigenin and luteolin have the ability to 
block molecular mechanisms involved in triggering the in-
flammatory response, especially the signalling pathway of 
the transcription factor NF-κB, which increases the expres-
sion of genes that encode proteins involved in obesity-related 
inflammation. Modulation of the cyclo-oxygenase (COX) 
pathway by inhibition of nitric oxide production seems to be 
the main anti-inflammatory mechanism of action exhibited 
by flavonoids [23]. 
 Benefits beyond those described above have been ob-
served for apigenin and kaempferol. In animal studies (Table 
2), apigenin reduced food intake of C57BL/6J mice by in-
creasing gene expression of anorexigenic neuropeptides [24]. 
The potential of kaempferol to increase energy expenditure 
should not be dismissed because this flavonoid may contrib-
ute to an increase in skeletal myocyte oxygen consumption 
of up to 30%, can affect regulation of metabolically impor-
tant genes and activate thyroid hormones [25].  
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Table 1. In Vitro Studies Showing Effects of Phenolic Compounds in the Modulation of Inflammatory Pathways and Adipogenesis 
Bioactive Compound Cell Type Dosage  Exposure Time Major Effects Reference
Macrophages 25 µM 24 h ↓ STAT-1 and NF-kB [16] 
Human endotelial 
cells  
5 - 50µM 24 h ↓ iNOS, COX-2, NF-kB and AP-1 [17] Kaempferol 
Adipocytes 3T3-L1 5 -m50µM 72 h ↑ PPAR-γ, ↑ glucose uptake [18] 
Luteolin 3T3-L1 adipocytes  0.1 - 20 μM 24 h ↑ PPAR-γ, ↑ insulin sensitivity [19] 
25 µM 30 min ↓TNF-α, IL-6, iNOS and COX-2 [20] 
Luteolin Macrophages 
1, 5, 10µM 24 h ↓ TNF-α and IL-6 [21] 
Apigenin 3T3-L1 adipocytes  1−50 μM 48 h Activation of AMPK and  ↓expression of adipogenic and lipolytic genes [22] 
Quercetin 3T3 – L1 adipocytes 10 – 100 μM 48 h 
Activating of MAPK pathway, induction of apoptosis in 
mature adipocytes and modulation ERK and JNK path-
ways of dose-dependent manner 
[30] 
Quercetin 25 μM ↓ lipid accumulation  [31] 
Quercetin and Resveratrol 25 μM ↓ lipid accumulation; ↓ PPAR-γ and C/EBP α  
Quercetin and Resveratrol 
3T3-L1 adipocytes 
100 μM 
24 and 48 h ↑ release of C cytochrome from mitochondria; ↓ phos-
phorylation of ERK  
Quercetin 
Human U937 mono-
cytes and human 
primary adipocytes  
3 - 30 μM 2.5 to 5 h 
↓ basal expression of inflammatory genes: TNF-α, IL-6, 
IL-8, IL-1b, interferon-γ inducible protein-10, and 
cyclooxygenase-2. Prevented inflammation-mediated 
insulin resistance in adipocytes  
[32] 
Resveratrol Human adipocytes 5- 100 μM 1- 4 d Inhibition of preadipocyte proliferation, inhibition of adipogenic differentiation, and inhibition of lipogenesis [38] 
3T3-L1 adipocytes  1 - 100 μM ↑ SIRT 1 ↓ fat accumulation 
50 μM ↓ fat accumulation 
Resveratrol 
Cells extracted from 
adipose tissue of male 
mice Sirt1+/+ and 
Sirt1+/− 
10 - 50 μM 
3 d 
↓ fat in retroperitoneal adipose tissue ↑ FFA and ↓ 
triglyceride accumulation 
[39] 
Curcumin 3T3-L1 adipocytes  5-100 μM Differenciation 
stage 
↓ expression of FAS, down-regulates the mRNA level 
of PPARγ and CD36, ↓ lipid accumulation [54] 
Curcumin 
3T3-L1 murine cells 
and in human primary 
preadipocytes 
5-30 μM 6 d Inhibition of mRNA levels of early adipogenic transcrip-
tion factors: KLF5, C/EBPα and PPARγ [55] 
Inhibition of cell proliferation 
↓ mRNA expression of PPARγ  Catechin 3T3-L1 adipocytes 5-200 μM 24 h 
↓ glycerol-3-phosphate dehydrogenase activity 
[61] 
↓ glucose uptake  
Catechin 3T3-L1 adipocytes 50 μM 30 min 
translocation of GLUT4 through activation of PI3K 
[62] 
↓, decrease; ↑, increase; STAT-1, signal transducers and activators of transcription; NF-kB, nuclear factor kappa B; iNOS, inducible nitric oxide synthase; 
COX-2, ciclooxigenase-2; AP-1, activator protein 1; PPAR-γ, peroxisome proliferator-activated receptors-γ; TNF-, tumour necrosis factor-; IL, interleukin; 
AMPk, AMP-activated protein kinase; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinases; JNK, c-Jun N-terminal protein 
kinases; C/EBPα, CCAAT/enhancer binding protein; SIRT1, sirtuin-1; FFA, free fatty acid. 
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Table 1. Contd….. 
Bioactive Compound Cell Type Dosage  
Exposure 
Time 
Major Effects Reference
Catechin 3T3-L1 adipocytes 0.1 - 10.0 μM 
Growth and 
differenciation 
phase 
↓ preadipocyte proliferation with dose dependent effect,
↓ expression of C/EBPα and PPARγ  [63] 
Clorogenic, o-cumaric and 
p-cumaric acids 
3T3-L1 pre-
adipocytes  
100 µM 72 h Cell cycle arrest in G1 phase [74] 
Galic acid 
3T3 – L1 adipo-
cytes  
250 μM 72 h 
Induction of apoptosis through the Fas and mitochon-
drial pathway; ↓ glycerol-3-phosphate dehydrogenase 
activity 
[75] 
 γ -orizanol acid Macrophages 1 mM 22 h Supression of NF-kB activation, ↓ inflammatory 
response 
[76] 
Hydroxycinnamic acid de-
rivatives 
3T3 – L1 adipo-
cytes  
1 μM 72 h Regulation of adiponectin secretion through inhibition 
of NF-kB activation 
[77] 
↓, decrease; ↑, increase; FAS, fatty acid synthase; CD36, scavenger receptor of macrophage; KLF5, Krüppel-like factor; C/EBPα, CCAAT/enhancer binding 
protein; PPAR-γ, peroxisome proliferator-activated receptors-γ; GLUT4, glucose transporter type-4; PI3K, Phosphoinositide 3-kinase ; NF-kB, nuclear factor 
kappa B. 
 
Table 2. In Vivo and Ex Vivo Studies on the Effects of Phenolic Compounds in the Modulation of Inflammatory Pathways and Adi-
pogenesis 
Bioactive 
Compound 
Cell Type Dosage  
Exposure 
Time 
Major Effects Reference
Apigenin C57BL/6J mice 
0.05% (w/w) in 
high-fat diet 
30 d 
↑anorexigen neuropeptides gene expression in neuronal 
cells, ↓ intake food [24] 
Kaempherol Wistar rats 
50 and 100 
mg/BW/d 
10 d ↓COX-2 and iNOS  [23]  
Quercetin Obese Zucker rats 10 mg/kg BW/d 10 wk ↑ adiponectin and ↓ TNF-α in visceral adipose tissue [27] 
Quercetin C57BL/6J mice  
0.8% of high-fat 
diet 
8 wk ↓ INF-γ, IL-1α and IL-4, ↑ TEE in the 3rt week  [34] 
Quercetin Male Wistar rats 
0.03% of high-fat 
diet  
4 wk 
↑ expression and secretion of adiponectin, ↑ glucose uptake 
,↓ RNAm PPAR-γ and ↓ 8-iso-PGF2α [35] 
Resveratrol C57BL/6NI mice  22.4 mg/ kg BW/d 1 year 
↑ insulin sensitivity, ↑ AMPK and UCP1, ↓ IGF-1, ↑ PGC-
1α [44] 
Resveratrol 
Primates (Microcebus muri-
nus) (n=6) 
200 mg/kg BW/d 4 wk ↓ 13% caloric intake, ↑ RMR from 12.7 to 29%, ↑ GLP-1  [45] 
Resveratrol Male C57BL/6J mice 
400 mg/ kg high-
fat diet  
10 wk 
↓ food intake, ↓visceral fat-pad weights, ↓adipocyte size in 
epididymal adipose tissue, ↓ serum lipids and improve 
markers of inflammation and insulin resistance 
[46] 
Resveratrol 
Male Wistar rats fed high-
fat diet 
30 mg/kg BW/d 6 wk ↓ 20% fat body, ↓triglycerides, ↑glycemic control [47] 
Resveratrol Healthy obese men (n=11) 150 mg/kg BW/d 30 d 
In muscle: activation AMPK, ↑SIRT1 and PGC-1α protein 
levels, ↑citrate synthase intramyocellular lipid content. 
↓intrahepatic lipid content, serum glucose, triglycerides, 
alanine-aminotransferase, and inflammation markers and 
HOMA index improvement  
[51] 
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Table 2. Contd….. 
Bioactive 
Compound 
Cell Type Dosage  
Exposure 
Time 
Major Effects Reference
Curcumin C57/BL mice 
500 mg/kg high-fat 
diet 
12 wk 
↓serum cholesterol and expression of PPAR- γ and 
CCAAT/enhancer binding protein alpha; suppression of 
angiogenesis in adipose tissue  
[56] 
    
↓ expression of vascular endothelial growth factor (VEGF) 
and its receptor VEGFR-2, ↓Body weight gain, adiposity, 
and microvessel density in adipose tissue 
 
Catechin 
Trial: 98 men and 99 women 
heatlhy (Japan) (IMC: 22.5 a 
30 kg/m²) 
Extract of green tea 
(665.9 mg/d) 
12 wk 
↓ body weight and BMI, ↓ waist perimeter and waist-hip 
ratio, ↓ total cholesterol and LDL-c [64] 
Catechin Trial: healthy men (n=38) 
Tea (690 mg cate-
chin/d) 
12 wk 
↓ body weight and BMI, ↓ waist perimeter and waist-hip 
ratio,  
↓ total cholesterol and LDL-c 
[65] 
Catechin 
Trial: men and women (Ja-
pan) with visceral obesity) 
(n=270) 
Green tea (583 mg 
catechin/d) 
12 wk 
↓ body weight and BMI , ↓waist perimeter and waist-hip 
ratio,  
↓ LDL-c and blood pressure  
[66] 
Catechin 
Cross-sectional: 569 men, 
641 women (Taiwan) 
435 mL green tea/d
≥ 10  
years 
Improved 19.6% glycemic control, ↓ 2.1% waist-hip ratio  [67] 
γ-orizanol acid C57BL/6J mice  14.5 µg/ml 
30, 54 and 
102 h after 
exposition 
Prevention of stress-induced hypoadiponectinemia and 
improvement o metabolic syndrome aggravated by chronic 
stress 
[78] 
Orizanol acid C57BL6J mice  
0.025 mM in 0,5 
mL of beef tallow 
or corn oil 
96 h after 
intake 
Reversal of hipoadiponectinemia induced by ingestion of 
animal fat 
[79] 
O-cumáric 
acid 
Wistar rats 100 mg/Kg diet 8 wk 
↓ body weight and epididimal and peritoneal adipose tissue 
↓ serum lipidis, ↓ insulin and leptin, ↓ oxidative stress  [80] 
Orizanol acid C57BL/6J mice 
0.5% oryzanol Or 
0.5% ferulic acid in 
high-fat diet 
7 wk 
↓blood glucose level, ↓ activities of enzymes glucose-6-
phosphatase and phosphoenolpyruvate carboxykinase, ↑ 
glycogen and insulin concentrations, ↑glucokinase activity, 
↓ body weight  
[81] 
Clorogenic 
acid 
ICR mice 0.2 g/kg de diet 8 wk 
Regulation of lipid metabolism in adipocyte through enzy-
matic inhibition of three enzymes: fatty acid synthase, 3-
hydroxy-3-methylglutaryl CoA reductase and acyl-CoA 
cholesterol acyltransferase 
[82] 
Galic acid Male Wistar rats  50 and 100 mg/kg 10 wk ↓ dyslipidemia, hepatic steatosis and oxidative stress [83] 
Clorogenic 
acid 
Trial: healthy individuals 
(IMC 27.5-32) (n= 12) 
11 g coffee en-
riched with cloro-
genic acid (90 – 
100 mg) / d 
12 wk ↓ body weight and fat percentage  [85] 
↓, decrease; ↑, increase; COX-2, ciclo-oxygenase2; iNOS, inducible nitric oxide synthase; TNF- α , tumor necrosis factor- α; INF-γ, interferon-gamma; IL, 
interleukin; TEE, total energy expenditure; PPAR-γ, peroxisome proliferator-activated receptors-γ; 8-isso-PGF2α, prostaglandin2;AMPK, AMP-activated 
protein kinase; UCP1, mitochondrial uncoupling proteins; IGF-1, insulin-like growth factor 1; PGC-1 α , peroxisome proliferator-activated receptor-gamma 
coactivator 1 alpha; RMR, resting metabolic rate; Sirt1, sirtuin-1; GLP-1, glucagon-like peptide-1; SIRT1, sirtuin-1; HOMA, homeostasis model assessment; 
VEGF, vascular endothelial growth factor; VEGFR-2, vascular endothelial growth factor receptor 2 
↓, decrease; ↑, increase; BMI, body mass index, LDL-c, low-density-lipoprotein cholesterol 
 It is noteworthy that most studies on these compounds 
have been performed In vitro with the aim to clarify mecha-
nisms of action; they have been focused on elucidating im-
plications for inflammation. Human intervention studies are 
needed to confirm the health benefits and to establish the 
dose-response relationship for kaempferol, apigenin and 
luteolin in obesity treatment.  
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Fig. (2). Chemical structures of bioactive compounds. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid. 
Quercetin 
 Quercetin (Fig. 2d) is a flavonoid that has been noted for 
beneficial effects on human health associated with its anti-
oxidant [26] and anti-inflammatory [27] properties. It may 
also modulate LDL-cholesterol levels [28] and blood pres-
sure [29]. 
 The anti-adipogenic effects of quercetin have been dem-
onstrated in 3T3-L1 and human adipocytes, whereas its anti-
inflammatory effects have been revealed in macrophages 
(Table 1). The main anti-adipogenic mechanism is the induc-
tion of apoptosis through modulation of extra-cellular signal-
regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) 
pathways [30]. When combined with resveratrol, quercetin 
has decreased lipid accumulation and inhibited PPAR-γ and 
C/EBP transcription factors. Both bioactive compounds, 
combined at concentrations of 100 µM, resulted in increased 
release of cytochrome C from mitochondria to the cytosol 
and decreased ERK phosphorylation [31]. In human cells, 
quercetin prevented inflammation and insulin resistance in 
adipocytes exposed to macrophage-conditioned media [32]. 
Indeed, there is evidence that quercetin is at least as effective 
as resveratrol at attenuating TNF-α-mediated inflammation 
and insulin resistance in primary human adipocytes [33]. 
 The anti-inflammatory effects of quercetin in adipose 
tissue have been confirmed in animal studies, as shown in 
Table 2. Its effects include evident improvement in the de-
gree of inflammation, increased plasma and mRNA levels of 
adiponectin, and decreased TNF-α production in visceral 
adipose tissue [27, 34, 35]. Thus, in mice fed a high fat diet 
(45%), a supplementation with 0.8% quercetin had no effect 
on body weight or body composition, but induced a reduc-
tion in the levels of inflammatory markers (IFN-γ, IL-1 α 
and IL-4) [34].  
 Beneficial effects of quercetin on energy metabolism and 
glucose uptake have also been observed. A transient increase 
on energy expenditure was observed during the third week of 
quercetin supplementation in mice fed with high-fat diet fol-
lowed by a reduction in circulating quercetin between weeks 
3 and 8, suggesting a metabolic adaptation to the early ef-
fects of quercetin on energy expenditure [34].  
 In high-fat-fed Wistar rats, a supplementation containing 
0.03% quercetin reduced fasting glucose levels, increased 
plasma and mRNA levels of adiponectin, decreased oxida-
tive stress in plasma (measured as 8-iso-PGF2a), and de-
creased PPAR-γ mRNA levels in adipose tissue [35]. These 
authors also observed that quercetin stimulated the secretion 
of adiponectin by mechanisms independent of PPAR-γ. 
 In summary, the anti-inflammatory, anti-oxidant and pro-
apoptotic effects of quercetin may prove to be useful in the 
treatment of obesity. The first and the second mechanisms 
are currently considered the primary instigators of patho-
physiological alterations related to the onset of metabolic 
syndrome. However, further human intervention studies are 
needed to confirm the efficacy of quercetin in reducing body 
fat and improving pathophysiological changes. In addition, it 
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is necessary to establish recommendation for adequate dos-
age and exposure times. 
Resveratrol 
 Resveratrol (Fig. 2e) is a phenolic compound that exhib-
its anti-inflammatory and cardioprotective effects that are 
partially attributed to its high anti-oxidant activity [36, 37]. 
Several in vitro and in vivo studies have demonstrated the 
effects of resveratrol in the regulation of adipogenic mecha-
nisms and inflammatory processes. 
 The results of the in vitro studies, as shown in Table 1, 
indicate that resveratrol exerts the following beneficial ef-
fects on obesity management: a decrease in lipid synthesis in 
adipocytes by PPAR-γ supression, an increase in lipolysis, 
and a reduction in lipid accumulation in maturing preadipo-
cytes [38, 39], through the inhibition of lipogenesis and dif-
ferentiation of 3T3-L1 adipocytes via activation of AMPK in 
a dose-dependent manner [40], and in the inhibition of adi-
pogenesis by means of GSH up-regulation [41]. 
 Through the mechanisms described above, resveratrol 
may decrease the expression and secretion of proinflam-
matory adipokines such as IL-6, TNF-α and PAI-1 [42], in-
crease the expression and secretion of adiponectin [43], and 
improve mitochondrial oxidative function by increasing sir-
tuin activity [38], mitochondrial biogenesis and fatty acid 
oxidation [39]. 
 The results of in vivo studies in rats (Table 2) have shown 
that resveratrol induces changes associated with longevity 
including increased insulin sensitivity, reduced levels of in-
sulin-like growth factor (IGF-1), increased AMPK and quan-
tity of mitochondria, increased activity of PGC-1α and im-
proved motor function of animals [44]. In primates, resvera-
trol reduced the body weight gain by increasing satiety and 
resting metabolic rate [45]. In mice fed with a high-fat diet, 
resveratrol decreased food intake and down-regulated 
adipogenic and inflammatory processes [46]. Intra-peritoneal 
administration of resveratrol in mice suppressed food intake 
by 20.0% and 17.2% for 24 and 48 h, respectively. The inhi-
bition of food intake was mediated by a down-regulation of 
neuropeptide Y and agouti-related protein, two neuropep-
tides involved in satiety [47]. 
 Still, the ability of resveratrol to induce a reduction in 
food intake has not been universally observed [45, 46, 48, 
49]. This difference could be attributed to the dose and pe-
riod of supplementation. However, even in short-term stud-
ies, and before weight reduction, resveratrol improved the 
metabolic state inherent to obesity [50]. In overweight sub-
jects, resveratrol also displayed several beneficial effects on 
muscle metabolism by reducing inflammatory markers and 
insulin resistance [51].  
 A consensus exists regarding the beneficial effects of 
resveratrol on adipogenesis mitigation. However, its benefits  
 
on obesity treatment should be further studied, focusing spe-
cial attention on the establishment of safe doses and the ade-
quate intake of this compound to attenuate inflammation and 
metabolic alterations. Data suggest that the potential thera-
peutic application of resveratrol as an adjunct in the obesity 
treatment should be exploited because, in addition to direct 
effects on adipocytes, its supposed appetite-reducing effect is 
very attractive. In clinical practice, unregulated appetite is a 
major constraint to the maintenance of body weight in obese 
individuals. 
Curcumin 
 Curcumin (Fig. 2f) is a polyphenol extracted from the 
rhizomes of turmeric (Curcuma longa L) [52]. It is known 
for its beneficial health effects attributed to anti-inflamma-
tory, anti-oxidant and hypolipidemic properties [53]. 
 Different in vitro assays (Table 1) have demonstrated that 
curcumin inhibits adipocyte differentiation [54, 55] and de-
creases lipid accumulation by reducing the expression of 
fatty acid synthase (FAS), as well as by down-regulating the 
PPAR-γ and CD36 mRNA levels during adipocyte differen-
tiation [54]. In C57/BL mice (Table 2), curcumin reduced 
body weight gain and adiposity, decreased serum cholesterol 
and caused suppression of angiogenesis in adipose tissue 
[56].  
 In addition to its direct action on the adipocyte, evidence 
has been shown that curcumin attenuates obesity-associated 
metabolic changes in the liver by blocking leptin signalling 
through reducing leptin receptor phosphorylation and induc-
ing an increase in adiponectin secretion, which is important 
for improving obesity-associated inflammation [57]. These 
results provide novel insights into the therapeutic mecha-
nisms of curcumin to improve hepatic metabolism and at-
tenuate changes associated with non-alcoholic steatohepatitis 
[58]. These effects have great therapeutic value due to the 
common occurrence of hepatic dysfunction in the obese.  
 A recent review concluded that curcumin may interact 
with proteins in adipocytes, down-regulating inflammatory 
adipocytokines, resistin and leptin, and up-regulating adi-
ponectin. The interactions of curcumin with several signal 
transduction pathways should reverse insulin resistance, hy-
perglycemia, hyperlipidemia, and other inflammatory symp-
toms associated with obesity and metabolic diseases [59]. 
Nevertheless, studies in humans are needed to explore the 
effects of curcumin in the treatment and control of metabolic 
abnormalities linked to obesity because knowledge at this 
level is still scarce.  
Catechins 
 Catechins (Fig. 2g), such as (−)-epicatechin, 3-O-galloyl-
(−)-epicatechin, (−)-epigallocatechin and epigallocatechin 3-
gallate (GEGC), are polyphenols present in high concentra-
tions in tea [60]. Green tea and catechins have been demon-
strated in cell culture (Table 1), human trials and cross-
sectional studies (Table 2) that may reduce adipocyte differ-
entiation and proliferation, lipogenesis [61-63], fat mass, 
body weight, oxidised LDL-c and blood pressure, and can 
improve glycemic control [64-67]. GEGC has been widely 
investigated for its possible body fat-reducing effects. 
 Evidences have shown that the anti-adipogenic effects of 
catechins are mediated by several mechanisms including the 
inhibition of cell proliferation, a decrease in PPAR-γ and 
C/EBP-α expression, an increase in glucose uptake [61-63], 
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and the induction of thermogenesis via sympathetic nervous 
system through inhibition of the enzyme catechol-O-
methyltransferase as well as noradrenaline enhancement 
[68]. Moreover, reduced body fat accumulation may also be 
explained by a decrease in the digestibility of the diet [69, 
70], higher faecal energy loss, increased post-prandial fat 
oxidation and a reduction in dietary lipid incorporation into 
adipose tissue, liver and skeletal muscle [70]. 
 These results have suggested the promising therapeutic 
potential of catechins in obesity management. Recent studies 
emphasise many benefits of beverages rich in catechins, in-
cluding the improvement of body composition and lower 
abdominal adiposity in moderately overweight subjects [71] 
and the attenuation of oxidative stress [72]. In diabetic sub-
jects, catechin-rich beverages have also contributed to reduc-
ing body weight, increasing adiponectin secretion and recov-
ering insulin-secretory ability [73]. 
 Despite evidence of health benefits from bioactive com-
pounds in tea, many doubts still remain regarding its poten-
tial in the treatment of obesity. The present review has veri-
fied that many different types of tea and different dose 
ranges reflecting varying levels of catechin ingestion were 
employed in studies to date. Moreover, the method of prepa-
ration and geographic origin of tea plants can influence cate-
chin content and, therefore, the bioactivity of each tea and its 
extracts. All of these factors should be taken into account in 
the use of green tea as an adjunct in obesity management.  
Phenolic acids 
 Phenolic acids (Fig. 2h) constitute a broad class of com-
pounds that are divided into two main groups, hydroxycin-
namic acids (caffeic, ferulic, coumaric and synaptic acids) 
and hydroxybenzoic acids (gallic, p-hydroxybenzoic, proto-
catechuic, vanillic and syringic acids) [60]. Among the bio-
logical activities of phenolic acids, their anti-oxidant and 
anti-inflammatory properties have attracted great attention. 
Additionally, adipose tissue is a target of action for phenolic 
acids as shown in the studies described in Tables 1 and 2.  
 In vitro studies (Table 1) using adipocytes and macro-
phages have revealed some of the mechanisms of action of 
phenolic compounds and their derivatives, which may ex-
plain the results observed in in vivo studies, such as the inhi-
bition of adipocyte proliferation, the inhibition of enzymes 
involved in carbohydrate metabolism and lipid pathways, the 
attenuation of inflammation and the consequent improve-
ment of adipocyte metabolism [74-77].  
 In vivo studies (Table 2) have revealed a reduction in 
inflammatory markers and oxidative stress, a decrease in 
body weight and improvements in carbohydrate and lipid 
metabolism by phenolic acid activity [78-85]. For example, 
hydroxycinnamic acids and their derivatives may regulate 
adiponectin secretion by inhibiting NF-kB and leukotriene 
formation [78], but they may also have anti-oxidant and anti-
glycation properties [86]. Ferulic acid and its derivative, 
gamma-oryzanol, reduced the risk of high-fat diet-induced 
hyperglycemia via regulation of insulin secretion and hepatic 
glucose-regulating enzyme activities [81]. A recent review 
has shown that ferulic acid derivatives may mediate anti-
inflammatory effects by down-regulating the pro-
inflammatory transcription factor NF-κB, which in turn can 
reduce the expression of inflammatory enzymes, such as 
COX-2 and iNOS, and pro-inflammatory cytokines, such as 
IL-1β, IL-6 and TNF-α. Moreover, these bioactive com-
pounds could up-regulate blood adiponectin levels via indi-
rect activation of PPAR-γ through NF-κB inhibition [87]. 
 In summary, the primary beneficial effects attributed to 
phenolic acids are due to their anti-oxidant activity, regula-
tion of adiponectin secretion, suppression of inflammatory 
responses, inhibition of the cell cycle and induction of adi-
pocyte apoptosis. However, most studies have been per-
formed in vitro or in animals. Human intervention studies are 
needed to investigate physiological effects and dose-
response, as well the synergistic action between several 
types of phenolic acids on metabolic alterations related to 
human obesity. It seems that derivatives of phenolic acids in 
the form of esters have greater pharmacological potential in 
adipose tissue [87, 88], and this must be further investigated. 
n-3 Long-chain Polyunsaturated Fatty Acids  
 Eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) (Fig. 2i) are polyunsaturated fatty acids (n-3) that 
have been highly investigated because of their functional 
properties in adipose tissue.  
 In vitro studies (Table 3) have shown that both fatty acids 
inhibit adipocyte differentiation, increase cell apoptosis, and 
up-regulate the expression of PPAR-γ, as well as proteins 
that enhance glucose uptake and improve insulin resistance 
[89-92]. Moreover, EPA has been shown to decrease the 
TNF-α-induced activation of lipolysis and NF-kB and 
ERK1/2 signalling pathways in 3T3-L1 adipocytes [93]. The 
beneficial metabolic effects of DHA and EPA have also been 
related to their ability to promote AMPK activation and to 
regulate adipokine secretion [94-96].  
 In vivo studies (Table 4) have demonstrated that EPA 
improves insulin resistance and hypolipidemia in animals fed 
a high-fat diet, reduces adipose tissue inflammation and vis-
ceral adiposity, increases adipocyte apoptosis and serum 
adiponectin, and up-regulates mitochondrial biogenesis, 
which may induce β-oxidation in white fat [97-101]. The 
reduction in retroperitoneal adipose tissue has aroused great 
interest since an increase in fat deposits in this area is highly 
associated with metabolic abnormalities related to obesity. 
 At concentrations commonly consumed in the diet, EPA 
and DHA have shown little effect on body composition in 
animals [102, 103]. However, the supplementation of fatty 
acids at a higher dosage, when associated with diets restric-
tive in energy, seems to potentiate weight loss [104, 105]. 
 Despite the evidence described above, human trials have 
not always demonstrate the benefits of EPA and DHA sup-
plementation in the treatment of obesity [106]. The dosage of 
fatty acid supplementation that could result in bioactivity 
necessary for obesity treatment is difficult to establish be-
cause these compounds are already present in the diet and 
have been combined in different proportions in each study. 
Distinct combinations and dietary influence can induce the 
anti-inflammatory effects of these fatty acids on the body. 
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Table 3. In Vitro Studies Showing Effects of n-3 Long-chain Polyunsaturated Fatty Acids and Lipoic Acid in the Modulation of 
Inflammatory Pathways and Adipogenesis 
Bioactive 
Compound 
Cell Type Dosage 
Exposure 
Time 
Major Effects Reference
DHA 3T3-L1 adipocytes 25 - 200 μM 10 d 
↓ glycerol-3-phosphate dehydrogenase, ↓ cell size and lipid 
accumulation of dose-dependent manner and ↑ apoptosis 
and ↑ lipolysis 
[89] 
DHA 3T3-L1 adipocytes 125 μM 24 h ↑ secretion and mRNA of adiponectin  [90] 
EPA 3T3-L1 adipocytes 200 μM 24 h  ↑ secretion and expression of apelin [91] 
EPA Human adipocytes 100 μM 48 h ↑ adiponectin secretion [92]  
EPA 
Primary rat and 3T3-L1 
adipocytes 
100 and  
200 μM 24 and 96 h
↓ IL-6-induced lipolysis, modulation of anti-inflammatory 
mechanisms involving protein phosphorylation  
[93, 96] 
EPA 
Primary cultured rat and 
3T3-L1 adipocytes 
200 μM 24 and 96 h Modulation (in visceral fat) of gene expression and protein 
secretion appointed as involved in insulin resistance 
[94] 
Alpha-lipoic 
acid  
3T3-L1 adipocytes 0.1 - 10 μM 24 h 
↑ mitochondrial mass, ↑ expression of mitochondrial DNA, 
↑ mitochondrial complexes, ↑ oxygen consumption and ↑ 
fatty acid oxidation 
[105] 
Alpha-lipoic 
acid 
3T3-L1 adipocytes 
100, 250 and 500 
μM 1, 2, 3, 6 d 
Modulation of adipocyte differentiation by regulation pro-
adipogenic transcription factors via mitogen-activated 
protein kinase pathways. Biphasic mode of LA action on 
mRNA levels of the adipogenic transcription factors 
[108] 
Alpha-lipoic 
acid  
3T3-L1 adipocytes 250 mM 1 h 
↑ phosphorylation of Sp1 and inhibition Sp1, transcrip-
tional activity, inhibition of leptin 
[109] 
Alpha-lipoic 
acid  
3T3-L1 adipocytes 250 μM 24 h ↑ apelin secretion [110] 
Alpha-lipoic 
acid  
T cells 50 and 100 µg/ml 5 min 
↓ IL-6 levels, ↓ IL-17 ,↓ inflammation via cAMP and pro-
tein kinase A signaling 
[111] 
↓, decrease; ↑, increase; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; IL, interleukin; LA; alpha-lipoic acid; Sp1, SV40 promoter-1; cAMP, cy-
clic adenosine monophosphate. 
Lipoic Acid 
  Lipoic acid (LA, Fig. 2j) is an organo-sulfur compound 
derived from caprylic acid that acts as a co-factor of mito-
chondrial enzymes. It is synthesised in the human body, but 
is also widely distributed in foods and has attracted much 
interest because of its anti-oxidant effects and therapeutic 
potential [107].  
 In vitro studies (Table 3) have demonstrated the effect of 
LA in modulating adipogenesis [108] and the production of 
adipokines, such as leptin, adiponectin and apelin. These 
alterations improve mitochondrial function by stimulating 
organelle biogenesis, increasing fatty acid oxidation and re-
ducing inflammation [109-111]. 
 Animal studies (Table 4) have demonstrated that LA can 
be beneficial for obesity management through different 
mechanisms including reduction of inflammation via cAMP 
and protein kinase A signalling, prevention of high-fat diet-
induced weight gain, slight increase in apelin expression, and 
decrease in intestinal sugar uptake and insulin resistance 
[110, 112, 113].  
 Human trials appear to confirm the beneficial effects of 
LA in obesity (Table 2). In obese subjects, supplementation 
with LA resulted in greater reduction in body weight, ab-
dominal circumference, and blood pressure [114, 115]. 
However, short-term LA supplementation did not prevent the 
lipid-induced dysregulation of glucose homeostasis in obese 
and overweight non-diabetic men [116].  
 These data reinforce the importance of better exploring 
the therapeutic value of LA in the treatment of obesity. Bi-
modal action depending on the LA concentration observed in 
vitro, needs to be investigated in vivo. 
DISCUSSION 
 As mentioned previously, in regards to obesity the dys-
function of the adipocyte leads to systemic metabolic conse-
quences that are triggered especially through pro-oxidant and 
pro-inflammatory mechanisms (Fig. 1). The present review 
confirms that different phenolic compounds and fatty acids 
share a common anti-oxidant effect in adipose tissue. This 
conclusion leads one to question the usefulness of oxidative 
stress reduction in adipose tissue as an approach to obesity 
management. Data appear to affirm this approach. Oxidative 
stress is considered one of the mechanisms responsible for 
the impairment of adipocyte function in obesity. It leads to 
the modulation of gene expression regulated by redox 
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Table 4. In Vivo and Ex-Vivo Studies Showing Effects of n-3 Long-chain Polyunsaturated Fatty Acids and Lipoic Acid in the Mod-
ulation of Inflammatory Pathways and Adipogenesis 
Bioactive 
Compound 
Cell Type Dosage  
Exposure 
Time 
Major Effects Reference
EPA C57BL/6J mice 
36 g/kg of high-fat 
diet 
11 wk 
↓ adipose inflammation and lipogenesis, ↑markers of fatty 
acid oxidation, ↓ saturated fat-induced insulin resistance  [97] 
EPA and DHA C57BL/6J mice 
6% EPA plus 51% 
DHA diet 
4wk 
↑ genes of mitochondrial proteins, ↑ expression of CTP-1 
gene  
↑ fatty acid oxidation in epididymal fat 
[98] 
EPA Wistar rats 1 g/kg/d 5wk 
↓ weigh body gain, ↓intake food, ↑ production of leptin, ↓ 
PPARγ, ↑ apoptosis; ↓ TNF-a, ↑ adiponectin [99] 
EPA 
Wistar rats: standard and 
high-fat diets 
1 g/kg/d 35 d ↓ retroperitoneal fat, ↓ epididymal fat, ↓ IL-6 mRNA [100] 
EPA 
Wistar rats: standard and 
high-fat diets 
1 g/kg/d 5 wk 
Down-regulation of genes involved in fatty acid synthesis: 
acetyl CoA carboxylase in muscle and liver fatty acid syn-
thase 
[101] 
Alpha-lipoic 
acid  
Wistar rats: standard and 
high-fat diets  
0.25 g LA/100 g 
of diet 
8 wk 
↑ apelin mRNA, ↓ intake food, ↓ fat mass, prevented obe-
sity 
[110] 
Alpha-lipoic 
acid  
Wistar rats fed high-fat diet  
0.25 g LA/100 g 
of diet 
8 wk 
Prevents body weight gain, reduces intestinal sugar trans-
port 
[112] 
Alpha-lipoic 
acid  
Wistar rats fed standard and 
high-fat diets  
0.25 g LA/100 g 
of diet 
8 wk 
↑adiponectin/total WAT ratio, ↑AMPK, negative correla-
tion between HOMA index and serum adiponectin/total 
WAT ratio 
[113] 
Alpha-lipoic 
acid  
Human trial 1200 mg LA 
6 h after 
intake 
Anti-inflammatory effects of LA are mediated in part by the 
cAMP/PKA signaling cascade 
[114] 
Alpha-lipoic 
acid  
Human trial: 1127 obese, 
and pre-obese individuals 
800 mg/d 120 d 
Higher reduction of body weight, abdominal circumference 
and blood pressure 
[115] 
Alpha-lipoic 
acid  
Human trial: 360 obese 
individuals 
1200 or 1800 
mg/d 
20 wk Significantly greater weight loss for 1800 mg/d [116] 
↓, decrease; ↑, increase; C; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; CTP-1, mitochondrial citrate transport protein; PPAR-γ, peroxisome 
proliferator-activated receptors-γ; TNF-α, tumour necrosis factor-α; IL- interleukin; WAT, white adipose tissue; HOMA; homeostasis model assessment; LA, 
lipoic acid; cAMP, cyclic adenosine monophosphate. 
mechanisms, especially those involved in inflammation and 
insulin signalling [117]. In fact, in obesity, the production of 
ROS is increased in adipose tissue [9] and enzymatic anti-
oxidant mechanisms are inhibited [118]. 
 Although the expression of several proteins can be modu-
lated by NBCs, the effect of prolonged exposure on the pro-
file of expressed genes remains unknown. Doubts remain as 
to whether the down- and up-regulatory mechanisms are 
permanent or transient; thus, recommendation cannot be 
made as to the best method of NBC exposure for obesity 
treatment: chronic or pulse exposures and dosages. All of 
this needs to be clarified in future studies. 
 This review (Tables 1, 2, 3 and 4) reveals that in in vitro 
assays, the exposure time of the adipocytes to the action of 
bioactive compounds varied between 5 minutes and 10 days. 
Similarly, in human and animal studies, the period of sup-
plementation ranged from 30 hours to 120 days. Long-term 
supplementation studies remain unavailable. 
 Another issue that merits discussion is the concentration 
of compounds used in these studies. Most NBCs in this re-
view are contained in foods at very low concentrations. Con-
sidering the numerous factors that affect their bioavailability 
in the human body, it is assumed that dietary intake of these 
NBCs through foods would not result in concentrations at 
the adipocyte comparable to those used in experimentation. 
Thus, many in vitro assays may be demonstrative of the 
pharmacological effects of these bioactive compounds and 
not the physiologically attainable levels. Moreover, little is 
known about the serum levels of such bioactive compounds 
in the general population and the concentrations reached in 
the target tissues. 
 All of these considerations suggest that to obtain the ef-
fects of these bioactive compounds as observed in the studies 
reviewed here, supplementation is the most adequate strat-
egy. For example, to increase the bioavailability of NBCs, 
nanoparticles of proteic or lipidic nature could be used [119]. 
Consequently, it is recommended that future studies test 
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lower concentrations of these bioactive compounds to clarify 
potential nano-bioactivity in the modulation of gene expres-
sion. Another approach is the study of synergistic effects via 
the combination of these NBCs. 
 The potential of NBCs to attenuate inflammation, prevent 
oxidative stress, and improve metabolic activity of the adi-
pocyte is an exciting approach to the treatment of obesity. 
Several mechanisms of great pathophysiological significance 
can be modulated by these compounds, especially oxidative 
stress, inflammation and adipocyte differentiation (Fig. 3). 
 The collected evidence suggests that the NBCs discussed 
in this review exhibit the ability to reduce inflammation and 
improve insulin resistance in adipose tissue through several 
mechanisms, such as increased lipid oxidation and stimula-
tion of mitochondrial biogenesis in adipose tissue as well as 
lipotropic effects in the liver. The latter effect should not be 
neglected, although this aspect is beyond the scope of this 
work. It is known that the metabolic changes that occur in 
the liver as a result of obesity are important mechanisms that 
underlie development of metabolic syndrome and insulin 
resistance [120]. 
 The traditional and simplistic idea that correction for the 
imbalance between caloric intake and energy expenditure is 
adequate treatment for obesity must be revolutionized. There 
is convincing scientific evidence that adipose tissue metabo-
lism is modulated by NBCs. This modulation results in bene-
ficial systemic effects by minimizing lipotoxicity in other 
tissues reducing the risk of comorbidities associated with 
obesity. However, it is noteworthy that the effects of NBCs 
should only be considered as adjuvants in the treatment of 
obesity. Gene modulation by NBCs can help to optimise 
therapy through intervention in the metabolic changes that 
hinder the success of treatment, support the obese state, and 
increase the risk of comorbidities. However, the restoration 
of energy balance by decreasing caloric intake and/or in-
creasing energy expenditure will always be the main objec-
tive in obesity treatment, something for which nutritional 
education remains crucial.  
CONCLUSION 
 The aforementioned food compounds may act on tran-
scriptional gene regulation, metabolic processes and hor-
mone levels by diverse mechanisms. Their primary activities 
involve reducing the inflammatory response and oxidative 
stress, decreasing insulin resistance and stimulating mito-
chondrial biogenesis and lipolysis. However, information 
from clinical studies to define the dose-response relationship, 
 
Fig. (3). Targets for action of phenolic compounds, EPA, DHA and lipoic acid to improve pathophysiological conditions in obesity.  
↓,  reduction;↑, increase;  EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid, LA, lipoic acid; TEE, total energy expenditure. 
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necessary time of exposure and potential side effects of these 
NBCs in the treatment of obesity is lacking. In conclusion, 
despite evidence that phenolic compounds, EPA, DHA, and 
LA have the potential to modulate the metabolic and secre-
tory functions of adipose tissue, which could lead to clini-
cally significant systemic effects in the management of obe-
sity, clinical studies are required to establish their effective 
and safe use.  
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